<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600247</url>
  </required_header>
  <id_info>
    <org_study_id>Duloxetine</org_study_id>
    <nct_id>NCT02600247</nct_id>
  </id_info>
  <brief_title>Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient</brief_title>
  <official_title>Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient : A Randomized, Controlled, Double-Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the effectiveness of duloxetine after total knee arthroplasty in
      Central sensitization patient. Central sensitization plays an important role in the chronic
      pain experienced by osteoarthritis patients.Elimination of the nociceptive input from the
      damaged joint by total joint arthroplasty was not always followed by a complete resolution of
      symptoms. Patients with high levels of preoperative pain and low pain thresholds had a higher
      risk of persistent pain after total knee arthroplasty (TKA), which has been interpreted as
      evidence of central sensitization. Thus, the presence of central sensitization before surgery
      in Osteoarthritis patients may be an important contributing factor to postoperative pain
      versus adequate analgesia. Preclinical models of central sensitization suggest that
      duloxetine is effective in the treatment of persistent pain. Investigators will compare the
      pain following TKA of central sensitization patients in duloxetine group (n=50) with those in
      non-duloxetine group (n=84). Investigators will classify the central sensitization patients
      by central sensitization inventory and divide the central sensitization patients in to 2
      groups (duloxetine and non-duloxetine group) randomly. Investigators checks the visual
      assessment scale at preoperative, postoperative 1, 2,6,12 weeks. All participants will
      receive postoperative pain control after TKA using the same pain control regimen except
      duloxetine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both groups of participants will receive pain control regimens as follows:

      Preemptive analgesia : celebrex celecoxib, Lyrica Pregabalin, Patient controlled analgesia
      (postoperation 28 hours), During admission : celebrex 200mg#1, Ircodon 5mg 2Tablets#2,
      Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1Capsule#1 x 5
      weeks, Ultracet 2T#2 x 1 week

      Drug generic names: celecoxib (celebrex), Pregabalin (Lyrica), acetaminophen/tramadol
      (ultracet ER), oxycodone (Ircodon)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual pain scale</measure>
    <time_frame>Preoperative &amp; postoperative 1, 2, 6, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF(Short form)- 36 scale(Preoperative and postoperative 6, 12 weeks)</measure>
    <time_frame>Preoperative and postoperative 6, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief pain inventory</measure>
    <time_frame>Preoperative and postoperative 1, 6, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Duloxetine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Duloxetine group
Phase I (preemptive): 1day before operation (30mg for 1 day)
Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>routine pain control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week
Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Experimental: Duloxetine group
Phase I (preemptive): 1day before operation (30mg for 1 day)
Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon
Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week
Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone</description>
    <arm_group_label>Duloxetine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone</intervention_name>
    <description>Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week
Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone</description>
    <arm_group_label>Duloxetine group</arm_group_label>
    <arm_group_label>routine pain control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients for total knee arthroplasty

          -  having medicare insurance

          -  CSI(Central sensitization inventory)&gt; 40 (Central sensitization patient )

        Exclusion Criteria:

          -  Rheumatoid arthritis

          -  Other inflammatory arthritis

          -  Neuropsychiatric patients

          -  Allergy or intolerance to study medications

          -  Patients with an ASA(American society of anesthesiologist) classification of IV
             (angina, congestive heart failure, dementia, cerebrovascular accident)

          -  Chronic gabapentin or pregabalin use (regular use for longer than 3 months)

          -  Chronic opioid use (taking opioids for longer than 3 months)

          -  Alcohol, drug abuser

          -  Narcotics addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong In, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tthe Catholic Univerisity of Korea Seoul St Mary's hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong In, MD, PhD</last_name>
    <phone>8290445228</phone>
    <email>iy1000@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mansoo Kim, MD</last_name>
    <phone>8272333875</phone>
    <email>kms3779@naver.com</email>
  </overall_contact_backup>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Yong In</investigator_full_name>
    <investigator_title>Proffesor</investigator_title>
  </responsible_party>
  <keyword>Total knee arthroplasty</keyword>
  <keyword>Duloxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

